(Q46614854)

23 December 2017

title

Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth (English)

1 reference

23 December 2017

0 references

Katsuyoshi Hori

1

1 reference

23 December 2017

Shozo Furumoto

series ordinal

2

1 reference

23 December 2017

Kazuo Kubota

series ordinal

3

1 reference

23 December 2017

publication date

29 April 2008

1 reference

23 December 2017

published in

Cancer Science

1 reference

23 December 2017

volume

99

1 reference

23 December 2017

page(s)

1485-1491

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

Vascular disrupting agents: a new class of drug in cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Augmentation of radiation response with the vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Tumor regrowth after irradiation; an experimental approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00834.X

10.1111/J.1349-7006.2008.00834.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18452559

1 reference

23 December 2017